Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 13Leukemia 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Myelodysplastic Syndromes 6Lymphoma 5Lymphoma, Non-Hodgkin 4Hodgkin Disease 4Congenital Abnormalities 4Lymphoma, Mantle-Cell 3Lymphoma, Large B-Cell, Diffuse 3Leukemia, Lymphocytic, Chronic, B-Cell 3Burkitt Lymphoma 3Neoplasms 2Multiple Myeloma 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma, B-Cell 2Leukemia, Prolymphocytic 2Leukemia, Myelomonocytic, Acute 2Leukemia, Monocytic, Acute 2Leukemia, Megakaryoblastic, Acute 2Leukemia, Erythroblastic, Acute 2Leukemia, Biphenotypic, Acute 2Immunoblastic Lymphadenopathy 2Sezary Syndrome 1Recurrence 1Preleukemia 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Mycosis Fungoides 1

Interventions

ruxolitinib 1filanesib 1Stem Cell Transplantation 1Melphalan 1Clofarabine 1CPI-0610 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Preleukemia × Clofarabine × Clear all
NCT00943592 2014-02-27

Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies

University of Chicago

Phase 1/2 Completed
82 enrolled 12 charts
Other hematologic neoplasm

Leukemia, Preleukemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡